Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

被引：52
|
作者：
Mizuno, Y
Yanagisawa, N
Kuno, S
Yamamoto, M
Hasegawa, K
Origasa, H
Kowa, H
机构：
[1] Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan
[2] Kanto Rosai Hosp, Kawasaki, Kanagawa, Japan
[3] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Sect, Kyoto, Japan
[4] Kagawa Prefectural Cent Hosp, Dept Neurol, Takamatsu, Kagawa, Japan
[5] Sagamihara Natl Hosp, Dept Neurol, Sagamihara, Kanagawa, Japan
[6] Toyama Med & Pharmaceut Univ, Fac Med, Div Biostat, Toyama, Japan
[7] Kitasato Univ, Tokyo, Japan
来源：
MOVEMENT DISORDERS | 2003年 / 18卷 / 10期
关键词：
Parkinson's disease; pramipexole; bromocriptine; levodopa; drug comparison; randomized controlled trial (RCT);
D O I：
10.1002/mds.10508
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (1311) group was included to enable determination of the noninferiority of PPX relative to 1311 as the standard treatment. (C) 2003 Movement Disorder Society.
引用
收藏
页码：1149 / 1156
页数：8
相关论文
共 50 条
  • [1] A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease
    Wermuth, L
    EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (03) : 235 - 242
  • [2] Rotigotine vs ropinirole in advanced stage Parkinson's disease: A double-blind study
    Mizuno, Yoshikuni
    Nomoto, Masahiro
    Hasegawa, Kazuko
    Hattori, Nobutaka
    Kondo, Tomoyoshi
    Murata, Miho
    Takeuchi, Masahiro
    Takahashi, Masayoshi
    Tomida, Takayuki
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (12) : 1388 - 1393
  • [3] Randomized, Double-Blind, Multicenter Evaluation of Pramipexole Extended Release Once Daily in Early Parkinson's Disease
    Hauser, Robert A.
    Schapira, Anthony H. V.
    Rascol, Olivier
    Barone, Paolo
    Mizuno, Yoshikuni
    Salin, Laurence
    Haaksma, Monika
    Juhel, Nolwenn
    Poewe, Werner
    MOVEMENT DISORDERS, 2010, 25 (15) : 2542 - 2549
  • [4] A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
    Wong, Kitty K.
    Alty, Jane E.
    Goy, Amanda G.
    Raghav, Sanjay
    Reutens, David C.
    Kempster, Peter A.
    MOVEMENT DISORDERS, 2011, 26 (08) : 1552 - 1555
  • [5] Transdermal Rotigotine in Early Stage Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Trial
    Mizuno, Yoshikuni
    Nomoto, Masahiro
    Kondo, Tomoyoshi
    Hasegawa, Kazuko
    Murata, Miho
    Takeuchi, Masahiro
    Ikeda, Junji
    Tomida, Takayuki
    Hattori, Nobutaka
    MOVEMENT DISORDERS, 2013, 28 (10) : 1447 - 1450
  • [6] A Randomized, Double-Blind, Placebo-Controlled Trial of Camicinal in Parkinson's Disease
    Marrinan, Sarah L.
    Otiker, Tal
    Vasist, Lakshmi S.
    Gibson, Rachel A.
    Sarai, Bhopinder K.
    Barton, Matthew E.
    Richards, Duncan B.
    Hellstrom, Per M.
    Nyholm, Dag
    Dukes, George E.
    Burn, David J.
    MOVEMENT DISORDERS, 2018, 33 (02) : 329 - 332
  • [7] A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease
    Ferreira, Joaquim J.
    Rascol, Olivier
    Poewe, Werner
    Sampaio, Cristina
    Rocha, Jose-Francisco
    Nunes, Teresa
    Almeida, Luis
    Soares-da-Silva, Patricio
    CNS NEUROSCIENCE & THERAPEUTICS, 2010, 16 (06) : 337 - 347
  • [8] The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled study
    Zhang, Zhenxin
    Wang, Jian
    Zhang, Xiaoying
    Chen, Shengdi
    Wang, Zhenfu
    Zhang, Baorong
    Liu, Chunfeng
    Qu, Qiumin
    Cheng, Yan
    Li, Jie
    Cao, Haijun
    Cai, Meng
    Zhu, Rongxuan
    PARKINSONISM & RELATED DISORDERS, 2013, 19 (11) : 1022 - 1026
  • [9] Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
    Alvarez-Nemegyei, J
    Cobarrubias-Cobos, A
    Escalante-Triay, F
    Sosa-Munoz, J
    Miranda, JM
    Jara, LJ
    LUPUS, 1998, 7 (06) : 414 - 419
  • [10] Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
    Lagalla, Giovanni
    Millevolte, Marzia
    Capecci, Marianna
    Provinciali, Leandro
    Ceravolo, Maria Gabriella
    MOVEMENT DISORDERS, 2006, 21 (05) : 704 - 707
12345